Please assess the completion status of the following clinical trial:

Trial Title: Natrecor in Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 18 to 85 years old.~2. Evidence of underlying lung disease by history and physical and/or chest x-ray and/or pulmonary function testing (PFT's).~3. PHTN documented by Doppler Echocardiography ( Done with in last 30 days)~4. Must be able to give an informed consent.~Exclusion Criteria:~1. Patients with clinically significant hypotension (defined as a systolic blood pressure (SBP) \<90).~2. Active infection or sepsis as defined by fever and need for IV antibiotics.~3. Creatinine greater than 3.0 mg/dl~4. Significant valvular disease as a cause for the PHTN.~5. Severe Thrombocytopenia (as defined by platelets less than 20,000 or INR \> 1.6.~6. Left Ventricle Ejection Fraction (LVEF) \<40% (must be done with in the last 30 days prior to signing consent).~7. Hypersensitivity to nesiritide or any of it's components.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nesiritide (Type: EXPERIMENTAL): Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).